Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

Keryx to Host Investor Conference Call on Friday, March 13, 2009 at 8:30am EDT

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2008.

At December 31, 2008, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.5 million, as compared to $62.4 million at December 31, 2007. In addition, at December 31, 2008, the Company had $7.2 million of auction rate securities which are classified as long-term investments.

The net loss for the fourth quarter ended December 31, 2008 was $3,807,000, or $0.08 per share, compared to a net loss of $29,261,000, or $0.67 per share, for the comparable quarter in 2007, representing a decrease in net loss of $25,454,000. The decrease in net loss was primarily attributable to a $14,076,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $7,013,000 and $2,735,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $1,385,000 decrease in other selling, general and administrative expenses, and a $562,000 decrease in non-cash compensation expense related to equity incentive grants, partially offset by a $1,011,000 decrease in interest and other income (expense), net.

The net loss for the year ended December 31, 2008 was $52,881,000, or $1.18 per share, compared to a net loss of $90,062,000, or $2.07 per share, for the year ended December 31, 2007, represe
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Remcom announces an ... with new features for the biomedical industry. The ... Biological Thermal Sensor, exclusive to the Bio-Pro version of ... of XFdtd, developed to calculate the biological effects of ... been added to all versions to expand engineers’ post-processing ...
(Date:8/26/2014)... San Diego, CA, and Bellingham, WA (PRWEB) August ... nanoscience and optical engineering, visions for next-generation wearable ... Light 2015 among numerous highlights at this year’s ... in the San Diego, California, Convention Center. More ... suppliers last week attended conferences, courses, an exhibition, ...
(Date:8/26/2014)... REHOVOT, Israel , August 26, 2014 /PRNewswire/ ... specialist, Replica 3DM, supports NHS hospitals with surgery validation using ... - Performing surgery on 3D printed models ... patient recovery and provides an effective aid for both patient ... (Nasdaq: SSYS ), a global leader of 3D ...
(Date:8/26/2014)... August 26, 2014 The global market ... million by 2020, according to a new study by ... and theranostics, and the subsequent introduction of advanced cancer ... market growth over the next six years. Moreover, the ... such as cancer, coupled with disease triggering lifestyle habits ...
Breaking Biology Technology:Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6
... TELK ) announced that its 2008 second quarter ... 11, 2008 at 4:30 p.m. Eastern time,(1:30 p.m. Pacific ... financial results for the second quarter ended June 30, ... Telik,s website at, http://www.telik.com or by telephone at ...
... Aug. 4 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... Bio-Tech Products (Shandong) Co., Ltd. (Kiwa Shandong),has ... China Organic Food,Certification Center (COFCC)., After ... appraisal of,Kiwa Shandong,s products, the China Organic ...
... Share Proposal is Best and Final Offer, INDIANAPOLIS, ... ) today reaffirmed that its $3.00 per share purchase ... its best and final offer,for the San Diego-based biotechnology ... signing of a definitive merger agreement, whereby,Lilly will acquire ...
Cached Biology Technology:Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 2Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 3Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3
(Date:8/26/2014)... increased risk of autism among children of women ... the known increased risk associated with severe maternal ... publication in Molecular Psychiatry , investigators from ... a diagnosis of autism spectrum disorder was more ... during pregnancy than in those with no prenatal ...
(Date:8/25/2014)... has experienced widespread adoption of robot-assisted prostate removal ... The BJU International study also found ... traditional surgeries, their costs are decreasing over time. ... in operations to remove the prostate. To examine ... prostatectomy (RARP) procedures for prostate cancer patients, Steven ...
(Date:8/25/2014)... Diego School of Medicine have found one of the ... a deadly brain cancer are resistant to drug therapy. ... tumor, but in its epigenetic signature. These findings have been ... Oncotarget . , "There is a growing interest to ... cell," said Clark Chen, MD, PhD, vice-chairman of Research and ...
Breaking Biology News(10 mins):Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2Finding keys to glioblastoma therapeutic resistance 2
... at the Texas A&M Health Science Center Institute ... Edinburgh have uncovered how a bacterial pathogen interacts ... methicillin-resistant Staphylococcus aureus (MRSA) infections, a ... the potentially deadly disease. Their work appears ...
... the wrong times, the results can be genetic disaster. ... in fruit flies that yank chromosomes, the DNA-carrying structures, ... condensin II, separate chromosomes by twisting them into supercoils ... Scientists had known of condensin II but did ...
... ON A new and insidious environmental threat ... researchers from Queen,s and York universities. Along ... team has documented biological damage caused by declining ... Calling the phenomenon "aquatic osteoporosis," Queen,s PhD ...
Cached Biology News:Keeping chromosomes from cuddling up 2Keeping chromosomes from cuddling up 3Queen's University biologists find new environmental threat in North American lakes 2
Acetylcholinesterase from human and monkey....
...
... Dye runs faster than Bromophenol blue,or ... gels.,Orange G dye migrates with DNA ... migration at this size,prevents the obscuring ... the front of DNA migration.,The Orange ...
... Gel loading solution, ... for non-denaturing polyacrylamide and ... nucleic acids and offers ... tracking dyes (bromphenol blue ...
Biology Products: